Skip to content
10-Q

Quarterly Report

Myovant Sciences Ltd.

0001679082-22-000032

← back to feed
Filed
Jan 26, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Jan 21, 2022 93.9M sh
Current Liabilities Q3 2022 · Dec 31, 2021 $269.04M
Current Liabilities Q3 2022 · Mar 31, 2021 $281.34M
Total Liabilities Q3 2022 · Dec 31, 2021 $1.04B
Total Liabilities Q3 2022 · Mar 31, 2021 $1.08B
Current Assets Q3 2022 · Dec 31, 2021 $574.75M
Current Assets Q3 2022 · Mar 31, 2021 $704.65M
Total Assets Q3 2022 · Dec 31, 2021 $604.29M
Total Assets Q3 2022 · Mar 31, 2021 $725.03M
Cash And Equivalents Q3 2022 · Mar 31, 2021 $674.49M
Cash And Equivalents Q3 2022 · Dec 31, 2020 $713.52M
Shares Diluted Q3 2022 · Dec 31, 2020 90.1M sh
Shares Diluted Q3 2022 · Dec 31, 2020 89.72M sh
Capex Q3 2022 · Dec 31, 2020 $1.04M
Operating Cash Flow Q3 2022 · Dec 31, 2020 $463.57M
Stockholders Equity Q3 2022 · Dec 31, 2020 −$270.66M
Stockholders Equity Q3 2022 · Sep 30, 2020 −$199.78M
Stockholders Equity Q3 2022 · Jun 30, 2020 −$134.61M
Stockholders Equity Q3 2022 · Mar 31, 2020 −$108.28M
Eps Diluted Q3 2022 · Dec 31, 2020 −$0.82
Eps Diluted Q3 2022 · Dec 31, 2020 −$1.94
Eps Basic Q3 2022 · Dec 31, 2020 −$0.82
Eps Basic Q3 2022 · Dec 31, 2020 −$1.94
Sga Expense Q3 2022 · Dec 31, 2020 $49.24M
Sga Expense Q3 2022 · Dec 31, 2020 $103.39M
Rd Expense Q3 2022 · Dec 31, 2020 $30.45M
Rd Expense Q3 2022 · Dec 31, 2020 $115.16M
Net Income Q3 2022 · Dec 31, 2020 −$73.85M
Net Income Q3 2022 · Dec 31, 2020 −$173.77M
Net Income Q3 2022 · Sep 30, 2020 −$67.06M
Net Income Q3 2022 · Jun 30, 2020 −$32.86M
Operating Income Q3 2022 · Dec 31, 2020 −$78.32M
Operating Income Q3 2022 · Dec 31, 2020 −$183.84M